Pilgrim's Corp
PPC
$28.77
+3.12%
Pilgrim's Pride is the second-largest poultry producer in the US, with operations spanning the UK and Mexico, selling fresh and prepared chicken and pork to chain restaurants, food processors, and retailers. Controlled by JBS (over 80% ownership), the company holds a dominant position in the protein value chain, leveraging scale and vertical integration. The current investor narrative centers on margin compression from volatile feed costs and pricing pressures, as evidenced by a sharp decline in gross margins from 15.0% in Q2 2025 to 9.5% in Q4 2025, raising concerns about earnings sustainability. Additionally, the failed JBS buyout in 2021 and ongoing shareholder structure debates add a layer of corporate governance overhang.…
PPC
Pilgrim's Corp
$28.77
Related headlines
Investment Opinion: Should I buy PPC Today?
Rating: Hold. The thesis is that PPC is a deep value stock with attractive multiples (trailing P/E 8.7x, P/S 0.51x) and a 7.0% FCF yield, but these are justified by deteriorating margins and decelerating growth. The consensus analyst rating is 'hold' with an average target of $34.19, implying 17.5% upside.
Supporting evidence: The trailing P/E of 8.7x is a 60% discount to the industry average of 22x. Revenue grew 3.3% YoY in Q4 2025, but net income fell 75.3% from Q2 2025. Gross margin compressed from 15.0% to 9.5%, and operating margin from 10.8% to 4.5%. Free cash flow yield of 7.0% provides a buffer, but the declining trend is concerning.
Risks & Conditions: The biggest risks are continued margin compression and revenue deceleration. This Hold would upgrade to Buy if gross margins stabilize above 12% and revenue growth re-accelerates above 5% YoY. It would downgrade to Sell if gross margins fall below 8% or the stock breaks below the 52-week low of $26.50. Valuation verdict: The stock appears undervalued on multiples but fairly valued given the fundamental deterioration.
Sign up to view all
PPC 12-Month Price Forecast
The AI assessment is bearish with medium confidence. The sharp margin compression and revenue deceleration are fundamental red flags that outweigh the deep valuation discount. The stock's low beta and high FCF yield provide some downside protection, but the deteriorating trend suggests further weakness is possible. A catalyst such as a margin recovery or buyout could shift the stance to neutral, but current data supports a cautious view.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pilgrim's Corp's 12-month outlook, with a consensus price target around $33.19 and implied upside of +15.3% versus the current price.
Average Target
$33.19
0 analysts
Implied Upside
+15.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$28 - $42
Analyst target range
The stock is covered by 8 analysts, with a consensus recommendation of 'hold' (mean rating 2.67 on a 1-5 scale, where 1 is strong buy). The average target price is $34.19, implying 17.5% upside from the current price of $29.11. The distribution shows no strong bullish or bearish bias, with most analysts at 'hold' or 'neutral'. The target range spans from $30.00 (low) to $42.00 (high), representing a 40% spread between low and high, indicating moderate uncertainty. The high target of $42.00 assumes a recovery in margins and a return to normalized earnings, while the low target of $30.00 prices in continued margin pressure and potential earnings downside. Recent ratings actions show no upgrades or downgrades in the past six months, with firms like BMO Capital and Barclays maintaining 'Market Perform' and 'Equal Weight' ratings. The lack of recent changes suggests analysts are in a wait-and-see mode, awaiting evidence of a margin recovery. The absence of strong buy recommendations and the hold consensus reflect the challenging fundamental outlook.
Bulls vs Bears: PPC Investment Factors
PPC presents a classic value trap debate: deep valuation multiples (trailing P/E 8.7x, P/S 0.51x) and a 7.0% FCF yield are offset by alarming margin compression (gross margin from 15.0% to 9.5%) and decelerating revenue growth (3.3% YoY). The bear case currently has stronger evidence, as deteriorating fundamentals justify the low multiples. The single most important tension is whether margins can stabilize or recover; if they do, the stock could re-rate significantly, but if they continue to decline, further downside toward the 52-week low of $26.50 is likely.
Bullish
- Deep Value Valuation: PPC trades at a trailing P/E of 8.7x and forward P/E of 9.2x, a 60% discount to the packaged foods industry average of ~22x. The P/S ratio of 0.51x and EV/EBITDA of 5.7x are also well below industry norms, suggesting the stock is pricing in significant pessimism.
- Strong Free Cash Flow Yield: TTM free cash flow is $660.6 million, yielding 7.0% on the current market cap. This provides a margin of safety and potential for shareholder returns, even amid margin compression.
- High ROE with Low Beta: ROE stands at 29.4%, indicating efficient capital use, while a beta of 0.3 means the stock is less volatile than the market, offering downside protection during broader selloffs.
- Analyst Target Upside: The average analyst target price is $34.19, implying 17.5% upside from the current $29.11. The high target of $42.00 suggests potential for a 44% gain if margins recover.
Bearish
- Sharp Margin Compression: Gross margin collapsed from 15.0% in Q2 2025 to 9.5% in Q4 2025, and net income fell 75.3% over the same period. Operating margin dropped from 10.8% to 4.5%, indicating severe cost or pricing pressure.
- Revenue Growth Deceleration: Q4 2025 revenue grew only 3.3% YoY, down from 9.1% YoY in Q2 2025. Sequential revenue declined from $4.757B to $4.518B, suggesting waning pricing power or volume weakness.
- Corporate Governance Overhang: JBS owns over 80% of shares, and a failed buyout in 2021 creates uncertainty. Minority shareholders have limited influence, and the controlling stake may deter some investors.
- Negative Price Momentum: The stock is down 35.4% over the past year, significantly underperforming the S&P 500's +18.4%. It trades near its 52-week low of $26.50, with no clear reversal signal.
PPC Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -35.4%, significantly underperforming the S&P 500's +18.4% gain. Currently trading at $29.11, it sits at 57.6% of its 52-week range ($26.50-$50.56), near the low end, suggesting either a potential value opportunity or continued weakness. The 52-week low of $26.50 is only 9.0% below the current price, indicating the stock is testing critical support levels. Short-term momentum shows a 1-month gain of +2.7%, contrasting with a 3-month decline of -14.2%, suggesting a tentative stabilization but no clear reversal. The 1-month relative strength of +2.37% versus the S&P 500 indicates slight outperformance recently, but the 3-month relative strength of -18.8% confirms the broader downtrend. The RSI is not directly provided, but the price action near the 52-week low suggests oversold conditions may be emerging. Key support is at the 52-week low of $26.50; a break below could signal further downside to the next psychological level of $25. Resistance is at the 52-week high of $50.56, representing a 73.7% upside from current levels. The beta of 0.3 indicates the stock is significantly less volatile than the market, meaning it may not participate fully in market rallies but also offers downside protection during selloffs. This low beta suggests the stock's movements are driven more by company-specific factors than broad market trends.
Beta
0.27
0.27x market volatility
Max Drawdown
-47.4%
Largest decline past year
52-Week Range
$26-$48
Price range past year
Annual Return
-40.0%
Cumulative gain past year
| Period | PPC Return | S&P 500 |
|---|---|---|
| 1m | -1.2% | +4.0% |
| 3m | +1.3% | +5.3% |
| 6m | -34.3% | +12.6% |
| 1y | -40.0% | +20.1% |
| ytd | -27.8% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PPC Fundamental Analysis
Revenue in Q4 2025 was $4.518 billion, up 3.3% year-over-year, but this growth decelerated from the 9.1% YoY growth seen in Q2 2025. The trailing twelve-month revenue trend shows a plateau around $18.5 billion, with sequential declines from Q2 2025's $4.757 billion to Q4 2025's $4.518 billion. Segment data reveals fresh product revenue of $2.923 billion (64.7% of total) and prepared products of $1.206 billion (26.7%), with export revenue of $276 million (6.1%). The growth deceleration is concerning, as it suggests pricing power may be waning in a competitive protein market. Profitability has deteriorated sharply: net income fell from $355.5 million in Q2 2025 to $87.9 million in Q4 2025, a 75.3% decline. Gross margin compressed from 15.0% in Q2 2025 to 9.5% in Q4 2025, well below the industry average for packaged foods (typically 20-30%). Operating margin also fell from 10.8% to 4.5% over the same period. The company remains profitable, but the margin trajectory is alarming and suggests input cost inflation or pricing pressure. The balance sheet shows a debt-to-equity ratio of 0.91, which is manageable but elevated for a consumer defensive company. Free cash flow (TTM) was $660.6 million, providing a free cash flow yield of 7.0% based on the current market cap. ROE is 29.4%, indicating strong returns on equity, but this is partly due to leverage. The current ratio of 1.47 suggests adequate liquidity, though it has declined from 2.01 a year ago. The company generated $291.2 million in operating cash flow in Q4 2025, covering capital expenditures of $269.9 million, but free cash flow was only $21.3 million, a sharp drop from $547.4 million in Q3 2024.
Quarterly Revenue
$4.5B
2025-12
Revenue YoY Growth
+3.3%
YoY Comparison
Gross Margin
9.5%
Latest Quarter
Free Cash Flow
$660584000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PPC Overvalued?
Since net income is positive ($87.9 million in Q4 2025), the primary valuation metric is the P/E ratio. The trailing P/E is 8.7x, while the forward P/E is 9.2x, implying the market expects earnings to decline slightly. The gap between trailing and forward P/E is narrow, suggesting limited growth expectations. Compared to the packaged foods industry average P/E of approximately 22x, Pilgrim's Pride trades at a 60% discount, reflecting its margin compression and earnings volatility. The P/S ratio of 0.51x is also well below the industry average of 1.5x, reinforcing the deep value nature of the stock. Historically, the trailing P/E has ranged from 5x to 46x over the past five years. The current 8.7x is near the low end of that range, suggesting the market is pricing in pessimistic expectations. The P/B ratio of 2.57x is above the book value, but below the historical average of 3.0x, indicating some value relative to assets. The EV/EBITDA of 5.7x is attractive compared to the industry average of 12x, but this reflects the depressed EBITDA margins. Overall, the valuation suggests the stock is cheap on an absolute and relative basis, but the low multiples are justified by the deteriorating fundamentals.
PE
8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
5.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is margin compression, with gross margin falling from 15.0% in Q2 2025 to 9.5% in Q4 2025, well below the industry average of 20-30%. Net income dropped 75.3% over the same period, and free cash flow in Q4 2025 was only $21.3 million, a sharp decline from $547.4 million a year earlier. The debt-to-equity ratio of 0.91 is manageable but elevated for a consumer defensive company, and the current ratio has declined from 2.01 to 1.47, indicating reduced liquidity.
Market & Competitive Risks: The stock's low beta of 0.3 suggests limited market correlation, but the 35.4% one-year decline reflects company-specific issues. Valuation compression risk is high given the stock trades at a 60% discount to industry P/E, but this discount could widen if margins deteriorate further. Competitive pressures from other protein producers and input cost volatility (feed costs) are ongoing headwinds. The failed JBS buyout in 2021 and controlling ownership structure create governance uncertainty that may limit investor interest.
Worst-Case Scenario: If margin compression continues due to rising feed costs and pricing pressure, earnings could fall further, pushing the stock to its 52-week low of $26.50 or below. A break below $26.50 could trigger further declines to $25.00, representing a 14% loss from the current price of $29.11. In a severe downturn, the stock could revisit historical lows near $20, implying a 31% downside. The max drawdown of -47.17% indicates the stock has experienced significant declines in the past.
FAQ
The key risks are: 1) Margin compression – gross margin fell from 15.0% to 9.5% in two quarters, and further declines could crush earnings. 2) Revenue deceleration – growth slowed from 9.1% to 3.3% YoY, indicating waning pricing power. 3) Corporate governance – JBS owns over 80% of shares, and the failed 2021 buyout creates uncertainty for minority holders. 4) Negative momentum – the stock is down 35.4% over the past year and trades near its 52-week low, with no clear catalyst for reversal. The most severe risk is a continued margin slide that pushes the stock below $26.50.
The 12-month outlook is mixed. The base case (50% probability) sees the stock trading between $30 and $34, near the analyst average target of $34.19, assuming margins stabilize at current levels. The bull case (20% probability) targets $34-$42 if margins recover and growth re-accelerates. The bear case (30% probability) sees the stock falling to $26.50-$30 if margins worsen. The most likely scenario is the base case, with the stock remaining range-bound due to the tug-of-war between deep value and weak fundamentals. The AI assessment is bearish with medium confidence, citing margin compression and revenue deceleration.
PPC appears undervalued on a multiples basis: trailing P/E of 8.7x is a 60% discount to the packaged foods industry average of 22x, and P/S of 0.51x is well below the industry 1.5x. However, this discount is justified by the company's deteriorating profitability, with net income down 75.3% from Q2 to Q4 2025. The market is pricing in continued margin pressure and low growth. Historically, the P/E has ranged from 5x to 46x over five years, so the current 8.7x is near the low end, suggesting the market is pessimistic. The stock is undervalued relative to history and peers, but the low multiples reflect real fundamental risks.
PPC is a high-risk, high-potential-reward stock. It trades at a deep discount (trailing P/E 8.7x vs. industry 22x) and offers a 7.0% FCF yield, but margins are compressing sharply (gross margin fell from 15.0% to 9.5% in two quarters). The consensus analyst rating is 'hold' with 17.5% upside to the average target of $34.19. It could be a good buy for contrarian investors willing to bet on a margin recovery, but it is not suitable for risk-averse investors. The biggest downside risk is further margin deterioration leading to a break below the 52-week low of $26.50.
PPC is more suitable for long-term investment, given its low beta of 0.3 and deep value characteristics. Short-term trading is risky due to negative momentum and lack of catalysts. The stock has a dividend yield of 0.21%, which is minimal, so income investors should look elsewhere. For long-term investors, the key is whether margins can recover; if they do, the stock could re-rate significantly. A minimum holding period of 2-3 years is recommended to allow for a potential turnaround. However, investors must be prepared for continued volatility and the risk of further declines toward the 52-week low of $26.50.